Itraconazole Dosage Adjustment for Disseminated Histoplasmosis

Understanding Itraconazole Therapeutic Levels

The Infectious Diseases Society of America recommends that blood levels of itraconazole should be obtained after at least 2 weeks of therapy to ensure adequate drug exposure 1
The target therapeutic level for itraconazole should be at least 1 μg/mL when measured by bioassay, as recommended by the Clinical Infectious Diseases society 3
Inadequate levels (<1 μg/mL) are associated with treatment failure and require dose adjustment, according to the Centers for Disease Control and Prevention 1, 2
Monitoring serum levels is especially important in cases of suspected treatment failure, concerns about absorption, or when using medications that may affect itraconazole metabolism, as stated by the Clinical Infectious Diseases society 3

For a patient with disseminated histoplasmosis on itraconazole 200 mg solution every 12 hours with inadequate levels, the dose should be increased to itraconazole 200 mg three times daily to achieve therapeutic levels of at least 1 μg/mL, as recommended by the Clinical Infectious Diseases society 1, 2
The American College of Physicians recommends that if levels remain subtherapeutic, consideration should be given to switching to a different formulation, ensuring medication is taken with food, ruling out drug interactions, and considering alternative therapy such as amphotericin B 2, 5

The Infectious Diseases Society of America states that inadequate itraconazole levels are a recognized indication for switching to amphotericin B therapy in disseminated histoplasmosis 6, 7
The Centers for Disease Control and Prevention recommends that the liquid formulation of itraconazole is preferred due to better absorption and fewer food interactions 2
Serial monitoring of serum or urine for Histoplasma antigen is useful for determining response to therapy, as recommended by the Clinical Infectious Diseases society 2
Treatment for disseminated histoplasmosis should continue for at least 12 months total, according to the Clinical Infectious Diseases society 1, 4
In immunosuppressed patients, lifelong suppressive therapy with itraconazole (200 mg daily) may be required if immunosuppression cannot be reversed, as stated by the Clinical Infectious Diseases society 1, 4

Failing to recheck itraconazole levels after dose adjustment is a common pitfall, as warned by the Clinical Infectious Diseases society 1
Not considering drug interactions that may affect itraconazole metabolism is another common pitfall, according to the Clinical Infectious Diseases society 3
Inadequate duration of therapy (less than 12 months for disseminated disease) is a common mistake, as cautioned by the Clinical Infectious Diseases society 1
Overlooking the need to monitor both clinical response and antigen levels during therapy is a pitfall to avoid, as recommended by the Centers for Disease Control and Prevention 2
Not recognizing that the solution formulation has better bioavailability than capsules is another common pitfall, as stated by the Centers for Disease Control and Prevention 2